脑脊髓液补充剂4级与非痴呆老年人的阿尔茨海默病病理学和认知有关
Jie Zhou1, Zhi-Bo Wang2, Yan Sun2
1Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, China.
Journal of Alzheimer's disease : JAD
|November 26, 2023
概括
大脑脊髓液补充4 (C4) 水平在临床前阿尔茨海默病 (AD) 中动态变化. 这些C4的变化与粉样蛋白病理有关,这表明在AD早期存在复杂的关系.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 补体系统显著影响阿尔茨海默氏症 (AD) 病变的发生.
- 补充4 (C4) 蛋白在脑脊液 (CSF) 中关于早期AD病理学的特定作用在很大程度上仍未确定.
研究的目的:
- 在临床前的AD中,调查脑脊液C4水平与AD核心生物标志物 (粉样β42,酸化,总) 之间的关联.
- 探索前临床AD的个体中CSF C4和随时间推移的认知变化之间的关系.
主要方法:
- 来自阿尔茨海默病神经成像计划 (ADNI) 队列的287名参与者的分析.
- 根据粉样/ (A/T) 方案将参与者分为四组,以评估CSF C4动态.
- 线性回归模型用于评估CSF C4和AD生物标志物之间的关联.
主要成果:
- 脑脊髓C4水平在临床前AD阶段表现出差异性变化,在A+T-组下降,在A-T+组增加.
- 在CSF C4和AD核心生物标志物之间观察到显著的关联,特别是在粉样蛋白阳性 (A+) 亚组内.
- 基线CSFC4水平与纵向认知衰退相关.
结论:
- 在临床前的AD期间,CSF C4水平呈现出动态变化.
- 脊髓C4对AD病理和神经退行症的影响取决于粉样斑块的存在.
- 这些发现突出了C4和阿尔茨海默病多方面的进展之间的复杂相互作用.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.9K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.4K
相关概念视频
Cerebrospinal Fluid
2.3K
Cerebrospinal fluid (CSF) is a colorless liquid that flows around the brain and the spinal cord, playing a vital role in the protection, support, and overall function of the central nervous system (CNS). CSF production, circulation, and absorption are tightly regulated processes essential for the brain and spinal cord to function properly.
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
2.3K
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Role of Neurotransmitters in Memory
574
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
574
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
